Landmark analysis of DNMT3A mutations in hematological malignancies
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Methylation of CpG islands is an epigenetic modification that is important for cellular development. 1 Different members of the DNMT gene family are involved in de novo CpG methylation. The DNMT3A gene is located on chromosome 2p23.3 and codes for a DNA methyltransferase. Ley et al. 1 and Yan et al. 2 were able to unravel DNMT3A mutations (DNMT3Amut) in acute myeloid leukemia (AML), thus supporting a role for aberrant DNA methylation to contribute to the pathogenesis of this disease. Subsequent studies detected DNMT3Amut in 17-34% of AML with normal karyotype (CN-AML) (see Table 1 ). Depending on the respective patient cohort characteristics, occurrence of the mutations was associated with an inferior survival (Table 1) . Subsequently, DNMT3Amut were studied and observed in other hematological malignancies ( With respect to data published by others, sequencing of only exons 15-23 is described. [5] [6] [7] However, in our cohort, 26/121 (21.5%) mutations occurred between exons 8 and 14, which emphasizes the need for sequencing of all three protein domains. The majority (95/121; 78.5%) of DNMT3Amut were missense mutations (AML: n ¼ 66, MDS: n ¼ 9, CMML: n ¼ 5, T-ALL: n ¼ 15). In addition, we observed 10 nonsense (n ¼ 1, (Figure 1b) .
Most samples showed a heterozygous (105/109 (96.3%)), whereas only 4/109 (3.7%) samples showed a homozygous mutation, which resulted in the loss of both wild-type alleles. Homozygous mutations were most common in T-ALL patients (3/17, 17.6%, Figure 1c) . A total of 97/109 (89.0%) patients harbored a single and 12 (11.0%) harbored two different DNMT3Amut. Occurrence of two mutations was most frequently observed in T-ALL samples (7/17; 41.2 vs 5/92; 5.4%, Po0.001). In total, loss of both wild-type alleles was detected in 10/17 of the T-ALL cases. In line with published data, codon 882 was most frequently affected. Here, the respective codon was altered in 37/75 AML (49.3%); 0/15 MDS; 2/7 CMML (28.6%) and 4/24 T-ALL cases (16.7%) (Figure 1e ).
Within the AML cohort, DNMT3Amut were more frequent in female than in male subjects (52.1 vs 21.0%, Po0.001) and were associated with younger age (mean, 57.4±15.0 vs 63.0±16.7 years, P ¼ 0.021). In T-ALL, DNMT3Amut were associated with normal karyotype (31.0 vs 12.5%, P ¼ 0.035), higher age (mean, 63.9 ± 15.7 vs 38.8 ± 14.3 years, Po0.001) and lower hemoglobin level (mean, 9.3±1.9 vs 11.5±3.4 g/dl, P ¼ 0.020). Within the CMML cohort, mutations were associated with female gender (15.6 vs 2.8%, P ¼ 0.029).
AML cases were further investigated for mutations in ASXL1
DNMT3Amut occurred more often together with NPM1mut, FLT3-ITD and IDH1 mutations (NPM1mut: 67.1 vs 23.4%, Po0.001, FLT3-ITD: 35.7 vs 18.7%, P ¼ 0.08, IDH1mut: 18.8 vs 4.3%, P ¼ 0.002), which was in accordance to the published data. 1 In contrast, DNMT3Amut were almost exclusive with ASXL1 and RUNX1 mutations (ASXL1: 6.3 vs 29.9%, P ¼ 0.001; RUNX1: 4.5 vs 20.5%, P ¼ 0.002). Associations with further molecular markers in MDS, CMML and T-ALL are presented in the Supplementary Appendix.
Finally, prognostic impact of DNMT3Amut was investigated in the different entities (Table 1 ). In our T-ALL cohort, patients with DNMT3Amut had worse overall survival (OS) as compared with wild-type patients (2-year OS: 35.2 vs 67.9%; median OS: 16.6 months vs not reached; P ¼ 0.013). No significant difference was observed between single-mutated and double-mutated/homozygous cases. In AML, no impact of DNMT3Amut on outcome was observed (2-year OS: 60.0 vs 58.0%; median OS: 62.2 vs 35.6 months; P ¼ n.s.; 2-year event-free survival: 34.2 vs 42.1%; median event-free survival: 13.6 vs 14.9 months; P ¼ n.s.). This was also true for DNMT3A-mutated cases within NPM1 mutated and/or FLT3-ITD cases. This was in contrast to previous studies (Table 1) showing an adverse prognostic impact for DNMT3Amut in AML, possible due to different patient composition. Further, no difference in outcome was observed between mutations affecting codon 882 and other DNMT3A alterations, as well as between age groups p60 years (n ¼ 79) and 460 years (n ¼ 115). Moreover, in MDS or CMML, we found no significant impact of DNMT3Amut on survival (Table 1) .
In summary, amongst the various hematological malignancies studied, DNMT3Amut showed the highest frequency in AML, where they were strongly associated with NPM1, FLT3-ITD and IDH1 mutations. This allows the hypothesis that these mutations interact in leukemogenesis. In T-ALL, DNMT3Amut were observed to be associated with worse OS (P ¼ 0.013), contrasting to AML, CMML and MDS. However, considering the fact that DNMT3Amut may interfere with epigenetic functions, deeper insights in these mutations may be helpful, considering the increased use of demethylation treatment strategies. 8 
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A Roller, V Grossmann, U Bacher, F Poetzinger, S Weissmann, N Nadarajah, L Boeck, W Kern, C Haferlach, S Schnittger, T Haferlach and A Kohlmann MLL Munich Leukemia Laboratory, Munich, Germany E-mail: alexander.kohlmann@mll.com As in other leukemia, abnormal expression of several miRNAs is reported in chronic myeloid leukaemia (CML). 2 Downregulation of miR10a leads to abnormal proliferation of CML cells through regulation of USF2 gene expression, whereas forced expression of miR-328 that is lost in the blast phase of the disease rescues C/EBP alpha-driven granulocytic maturation and impairs survival of CML cells. 3, 4 Recently, one of the miRNA that is attracting considerable attention in hematopoiesis is miR-223 as it resembles a myeloid gene and its expression is known to increase towards myeloid differentiation. Expression of miR-223, which was identified bioinformatically, is controlled by three transcription factors, C/EBPa, PU.1 and NFI-A. C/ EBP-a and PU.1 positively regulates miR-223, whereas NFI-A competes for C/EBPa binding site and maintains miR-223 at low levels. 5, 6 BCR-ABL inhibits the translation of C/EBPa mRNA by stabilizing the RNA-binding protein hnRNP E2. 7 As CML is characterized by chronic granulocytic maturation arrest and the transcription factors involved in miR-223 expression are deregulated in CML, we predicted that miR-223 may have a role in CML disease biology.
We investigated the miR-223 and BCR-ABL expression pattern in the peripheral blood samples from CML patients (n ¼ 35) by real-time quantitative PCR (RQ-PCR). Relative expression values for each sample were calculated by using 2 À DCt method. Spearman's correlation test shows the existence of a negative correlation between the expression profiles of BCR-ABL and miR-223 (Figure 1a) . To further validate this, bone marrow mononuclear cells from three untreated CML patients were isolated and treated with 2 mM imatinib, a BCR-ABL kinase inhibitor. After 48 h of treatment, miR-223 expression was analyzed by RQ-PCR. MiR-223 expression was upregulated in imatinib-treated bone marrow mononuclear cells as compared with dimethyl sulfoxide control (Figure 1b) . Hence, these studies support the notion that BCR-ABL mediates repression of miR-223, probably, by deregulating C/EBPa. However, normal and complete hematological response (CHR) cases failed to show any appreciable correlation with naive CML cases as because of the different cell type.
MiR-223 relative expression was correlated in CML with the available clinical parameters. Among the available clinical data, sokal score and neutrophil percentage were found to be significant. MiR-223 expression was positively correlated with mature neutrophil percentage, and this data also supports the role of miR-223 in granulocytic maturation as shown by Fazi et al. 6 (data not shown). Spearman's correlation test demonstrated the existence of a negative correlation between miR-223 expression levels and sokal score. This suggests that miR-223 expression is negatively correlated with disease risk (Figure 1c ) and may be used as a disease-risk prediction marker.
To define the role of miR-223 in CML, we generated a cell line model system in which K562 cells were transduced with a lentiviral vector expressing miR-223. After 7 days of transduction, K562 cells were analyzed for miR-223 expression to confirm the overexpression of miR-223 (Figure 1d) . To verify the role of miR-223 in granulocytic maturation, we analyzed myeloperoxidase expression at the RNA level. Figure 1e shows that MPO is upregulated at mRNA level in 
